Spero Therapeutics (SPRO) and GSK (GSK) said Wednesday that a phase 3 trial of tebipenem HBr, an investigational oral antibiotic for complicated urinary tract infections, including pyelonephritis, met its primary endpoint and will end early due to efficacy.
Shares of Spero catapulted 228% as intraday trading volume soared to over 166.9 million from a daily average of about 131,000.
Signing Day Sports (SGN) said Wednesday that it has signed a definitive business combination agreement to buy One Blockchain, the operating affiliate company of data hosting firm BlockchAIn Digital Infrastructure.
Shares of Signing Day soared 178%, with intraday trading volume at over 153.2 million compared with a daily average of roughly 1.7 million.
Aspire Biopharma (ASBP) said Wednesday it expects to launch Buzz Bomb, its sublingual pre-workout supplement, in Q3.
Shares surged 148% as intraday trading volume advanced to more than 567.3 million from a daily average of about 739,000.
Price: 2.24, Change: +1.56, Percent Change: +228.45
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。